NASD · Healthcare · Medical Devices · USA
Anteris Technologies Global Corp is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.
Anteris Technologies Global Corp develops the DurAVR THV System, a transcatheter aortic valve replacement device for treating aortic stenosis. The system combines a single-piece biomimetic valve manufactured with proprietary ADAPT tissue technology and a balloon-expandable delivery mechanism. The company is conducting the PARADIGM Trial to evaluate the device's safety and efficacy.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Anteris Technologies Global Corp stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.
16 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
61 more in this industry show a wider margin of safety.
We do not publish a verdict on AVR yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.